Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Predicting the efficacy of variant-modified COVID-19 vaccine boosters
David S. Khoury, Steffen S. Docken, Kanta Subbarao, et al.
Nature Medicine (2023) Vol. 29, Iss. 3, pp. 574-578
Open Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines
Magnus A. G. Hoffmann, Zhi Yang, Kathryn E. Huey‐Tubman, et al.
Cell (2023) Vol. 186, Iss. 11, pp. 2380-2391.e9
Open Access | Times Cited: 42
Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children
Youjia Zhong, Alicia Kang, Carina Jing Xuan Tay, et al.
Nature Medicine (2024) Vol. 30, Iss. 5, pp. 1373-1383
Open Access | Times Cited: 17
Covid-19 Reinfections Case Series from October 2023 to October 2024 in A General Medicine Office in Toledo (Spain)
José Luis Turabián
Epidemiology International Journal (2025) Vol. 9, Iss. 1, pp. 1-7
Open Access | Times Cited: 1
Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada
Danuta M. Skowronski, Samantha E Kaweski, Michael A. Irvine, et al.
Canadian Medical Association Journal (2022) Vol. 194, Iss. 47, pp. E1599-E1609
Open Access | Times Cited: 45
Immune imprinting and next-generation coronavirus vaccines
Chloe Qingzhou Huang, Sneha Vishwanath, George Carnell, et al.
Nature Microbiology (2023) Vol. 8, Iss. 11, pp. 1971-1985
Closed Access | Times Cited: 38
Immune Imprinting and Implications for COVID-19
Zhiqian Zhou, Julia Barrett, Xuan He
Vaccines (2023) Vol. 11, Iss. 4, pp. 875-875
Open Access | Times Cited: 27
Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters
Luca M. Zaeck, Ngoc H. Tan, Wim J. R. Rietdijk, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
SARS-CoV-2-specific cellular and humoral immunity after bivalent BA.4/5 COVID-19-vaccination in previously infected and non-infected individuals
Rebecca Urschel, Saskia Bronder, Verena Klemis, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Sho Iketani, David D. Ho
Cell chemical biology (2024) Vol. 31, Iss. 4, pp. 632-657
Open Access | Times Cited: 7
Epidemiologic and economic modelling of optimal COVID-19 policy: public health and social measures, masks and vaccines in Victoria, Australia
Joshua Szanyi, Tim Wilson, Samantha Howe, et al.
The Lancet Regional Health - Western Pacific (2023) Vol. 32, pp. 100675-100675
Open Access | Times Cited: 15
Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign
Marianne Shawe‐Taylor, David Greenwood, Agnieszka Hobbs, et al.
The Lancet (2024) Vol. 403, Iss. 10432, pp. 1133-1136
Open Access | Times Cited: 6
The effect of COVID-19 vaccine to the Omicron variant in children and adolescents: a systematic review and meta-analysis
Wenting Lu, Shuai Zeng, Yuan Yao, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access | Times Cited: 6
Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals
Alexander A. Cohen, Jennifer R. Keeffe, Ariën Schiepers, et al.
Cell (2024) Vol. 187, Iss. 20, pp. 5554-5571.e19
Open Access | Times Cited: 6
Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals
Alexander A. Cohen, Jennifer R. Keeffe, Ariën Schiepers, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 5
Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial
Juleen Gayed, Vishva Bangad, Xia Xu, et al.
Vaccines (2024) Vol. 12, Iss. 7, pp. 734-734
Open Access | Times Cited: 5
Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques
Christopher T Edwards, Kirti A. Karunakaran, Elijah Garcia, et al.
PLoS Pathogens (2025) Vol. 21, Iss. 1, pp. e1012456-e1012456
Open Access
The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose
Nadia Mazarakis, Zheng Quan Toh, Eleanor Neal, et al.
Journal of Infection (2025), pp. 106447-106447
Open Access
Longitudinal analysis of antibody titers after primary and booster mRNA COVID-19 vaccination can identify individuals at risk for breakthrough infection
Hyeongki Park, Naotoshi Nakamura, Shô Miyamoto, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
SARS-CoV-2 conjugate vaccine elicits robust immune responses that can protect against evolving variants.
Melanie L. Carroll, Heather Fox, Anh Tran, et al.
Vaccine (2025) Vol. 54, pp. 126988-126988
Open Access
Estimating long-term vaccine effectiveness against SARS-CoV-2 variants: a model-based approach
Alexandra B. Hogan, Patrick Doohan, Sean L. Wu, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 13
Predicting Vaccine Effectiveness for Hospitalization and Symptomatic Disease for Novel SARS-CoV-2 Variants Using Neutralizing Antibody Titers
Billy J. Gardner, A. Marm Kilpatrick
Viruses (2024) Vol. 16, Iss. 3, pp. 479-479
Open Access | Times Cited: 4
Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses
Mitch Brinkkemper, Tim S. Veth, Philip J. M. Brouwer, et al.
iScience (2022) Vol. 25, Iss. 12, pp. 105649-105649
Open Access | Times Cited: 19
Preexisting immunity restricts mucosal antibody recognition of SARS-CoV-2 and Fc profiles during breakthrough infections
Kevin J. Selva, Pradhipa Ramanathan, Ebene R. Haycroft, et al.
JCI Insight (2023) Vol. 8, Iss. 18
Open Access | Times Cited: 10
Mathematical modeling to investigate the influence of vaccination and booster doses on the spread of Omicron
K Kavya, P. Veeresha, Hacı Mehmet Başkonuş, et al.
Communications in Nonlinear Science and Numerical Simulation (2023) Vol. 130, pp. 107755-107755
Closed Access | Times Cited: 10
Anti–SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021–June 2022
Kelsey M. Sumner, Ruchi Yadav, Emma K. Noble, et al.
The Journal of Infectious Diseases (2024) Vol. 230, Iss. 1, pp. 45-54
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top